通过心力衰竭中PPARα通路调节,恩帕格利弗洛辛的心能保护作用
Hua Wei1,2,3, Menghua Yin1, Junshun Chang1
1Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Frontiers in pharmacology
|November 3, 2025
概括
恩帕格利弗洛辛通过将心脏代谢从葡萄糖转移到脂质来改善心力衰竭 (HF),18F-FDG MicroPET/CT成像显示. 这项研究揭示了empagliflozin.
科学领域:
- 心血管医学 心血管医学
- 代谢成像 - 代谢成像
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 涉及复杂的病理和心脏能量代谢的改变.
- PPARα信号通路对于调节高频的能量代谢至关重要.
- SGLT2 抑制剂代表了一种新的治疗类型,用于不完全理解机制的HF.
研究的目的:
- 通过使用18F-FDG微PET/CT成像来研究慢性HF中PPARα信号通路的变化.
- 通过PPARα途径阐明SGLT2抑制剂治疗高压大鼠的机制.
- 建立用于诊断高频能量代谢变化的成像基础.
主要方法:
- 在慢性心力衰竭的老鼠模型中利用18F-FDG MicroPET/CT进行心肌代谢成像.
- 在使用empagliflozin (EMPG) 或 fenofibrate (FF) 治疗之前和之后的量化心肌葡萄糖代谢率 (MRGlu).
- 评估了脂质 (PPARα,RXRα,CPT1α,CD36) 和能量代谢 (AMPKα,sirt1,GLUT4) 途径中的关键蛋白的表达.
主要成果:
- 与健康对照组相比,HF大鼠显示MRGlu显著增加和代谢蛋白的表达改变.
- 恩帕格利弗洛辛治疗显著降低了MRGlu和葡萄糖的吸收,同时促进了脂质代谢途径.
- 恩帕格利弗洛辛在改善心脏能量代谢和减少HF大鼠纤维化方面表现出比芬诺纤维酸更高的疗效.
结论:
- 肝炎的特征是心肌糖代谢 (MRGlu) 的增加.
- 恩帕格利弗洛辛通过抑制葡萄糖代谢和促进脂质代谢,增强心脏能量供应来改善慢性HF.
- 18F-FDG MicroPET/CT成像有效地可视化高频能量代谢变化,MRGlu提供定量诊断数据.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
909
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
909
01:25cAMP-dependent Protein Kinase Pathways
8.3K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.3K
01:30Heart Failure V: Medical Management
208
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
208
01:29Heart Failure II: Pathophysiology
699
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
699
01:22Heart Failure Drugs: β-Blockers
755
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
755
01:23Dipeptidyl Peptidase 4 Inhibitors
574
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
574